Actively Recruiting
Post-Marketing Study of Danicopan as Add-On Therapy to C5 Inhibitors in Patients with Paroxysmal Nocturnal Hemoglobinuria in Korea
Led by AstraZeneca · Updated on 2026-10-13
27
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety and effectiveness of Danicopan when added to C5 inhibitor treatments Eculizumab or Ravulizumab in patients with Paroxysmal Nocturnal Hemoglobinuria PNH in a routine clinical setting in Korea. The study fulfills a post-approval requirement by the Korean health authority to better understand the drugs safety profile and identify any unexpected adverse effects in real-world practice. Participants will receive Danicopan as an add-on therapy to their existing C5 inhibitor treatment according to approved indications. The study observes patients during routine medical care without additional interventions, focusing on the known safety profile and effectiveness. Effectiveness evaluations occur at 12 and 24 weeks, with safety data collected for up to 24 weeks from the start of Danicopan treatment. During the study, participants will be monitored for adverse events, serious adverse events, and adverse drug reactions. Effectiveness assessments include changes in hemoglobin levels, reticulocyte counts, fatigue scores, and transfusion avoidance rates at 12 and 24 weeks. Data collection aligns with standard clinical visits, and participants are observed under typical medical practice conditions until the study ends in June 2028.
CONDITIONS
Brief Title
Danicopan PMS in Korea
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here